Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Neutrophil Extracellular Traps (NETs) have been implicated in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) pathogenesis. The myeloperoxidase–deoxyribonucleic acid (MPO-DNA) complex and nucleosomes are serum markers of NETosis. The aim of this study was to assess these NETosis parameters as markers for SLE and APS diagnosis and their association with clinical features and disease activity. A total of 138 people were included in the cross-sectional study: 30 with SLE without APS, 47 with SLE and APS, 41 patients with primary antiphospholipid syndrome (PAPS), and 20 seemingly healthy individuals. Serum MPO-DNA complex and nucleosome levels were determined via an enzyme-linked immunosorbent assay (ELISA). Informed consent was obtained from all subjects involved in the study. The Ethics Committee of the V.A. Nasonova Research Institute of Rheumatology (Protocol No. 25 dated 23 December 2021) approved the study. In patients with SLE without APS, the levels of the MPO-DNA complex were significantly higher compared to patients with SLE with APS, with PAPS, and healthy controls (p < 0.0001). Among patients with a reliable diagnosis of SLE, 30 had positive values of the MPO-DNA complex, of whom 18 had SLE without APS, and 12 had SLE with APS. Patients with SLE and positive MPO-DNA complex levels were significantly more likely to have high SLE activity (χ2 = 5.25, p = 0.037), lupus glomerulonephritis (χ2 = 6.82, p = 0.009), positive antibodies to dsDNA (χ2 = 4.82, p = 0.036), and hypocomplementemia (χ2 = 6.72, p = 0.01). Elevated MPO-DNA levels were observed in 22 patients with APS: 12 with SLE with APS and 10 with PAPS. There were no significant associations between positive levels of the MPO-DNA complex and clinical and laboratory manifestations of APS. The concentration of nucleosomes was significantly lower in the group of SLE patients (±APS) compared to controls and PAPS (p < 0.0001). In SLE patients, the frequency of low nucleosome levels was associated with high SLE activity (χ2 = 13.4, p < 0.0001), lupus nephritis (χ2 = 4.1, p = 0.043), and arthritis (χ2 = 3.89, p = 0.048). An increase in the specific marker of NETosis, the MPO-DNA complex, was found in the blood serum of SLE patients without APS. Elevated levels of the MPO-DNA complex can be regarded as a promising biomarker of lupus nephritis, disease activity, and immunological disorders in SLE patients. Lower levels of nucleosomes were significantly associated with SLE (±APS). Low nucleosome levels were more common in patients with high SLE activity, lupus nephritis, and arthritis.

[1]  A. Ibrahim,et al.  Retrospective cohort study of thromboembolic events in systemic lupus erythematosus with or without secondary antiphospholipid syndrome and their correlation to lupus activity and dyslipidemia , 2023, Egyptian Rheumatology and Rehabilitation.

[2]  P. Skendros,et al.  Methods for the Assessment of NET Formation: From Neutrophil Biology to Translational Research , 2022, International journal of molecular sciences.

[3]  Y. Tsuchida,et al.  Serum extracellular traps associate with the activation of myeloid cells in SLE patients with the low level of anti-DNA antibodies , 2022, Scientific Reports.

[4]  S. Soloviev,et al.  Systemic lupus erythematosus: history and modernity , 2022, Rheumatology Science and Practice.

[5]  B. W. Hounkpe,et al.  Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome. , 2022, Thrombosis research.

[6]  D. Karp,et al.  Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients , 2022, Chinese medical journal.

[7]  Yaqi Wang,et al.  The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies , 2021, Clinical Reviews in Allergy & Immunology.

[8]  N. Barbarroja,et al.  Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation , 2021, Arteriosclerosis, thrombosis, and vascular biology.

[9]  S. Massberg,et al.  Interplay between inflammation and thrombosis in cardiovascular pathology , 2021, Nature Reviews Cardiology.

[10]  R. Toes,et al.  Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses , 2020, Cells.

[11]  J. Basílio,et al.  Altered platelet proteome in lupus anticoagulant (LA)-positive patients—protein disulfide isomerase and NETosis as new players in LA-related thrombosis , 2020, Experimental & Molecular Medicine.

[12]  A. Bengtsson,et al.  Neutrophils—Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome , 2019, Front. Immunol..

[13]  D. Radojkovic,et al.  Neutrophil extracellular traps-associated markers are elevated in patients with systemic lupus erythematosus , 2019, Rheumatology International.

[14]  F. Scolari,et al.  Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis , 2019, The Journal of Rheumatology.

[15]  D. El-Ghoneimy,et al.  The behavior of neutrophil extracellular traps and NADPH oxidative activity in pediatric systemic lupus erythematosus: relation to disease activity and lupus nephritis , 2019, Clinical Rheumatology.

[16]  T. Radstake,et al.  Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome , 2018, Rheumatology.

[17]  M. Christ-Crain,et al.  Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial , 2018, European Respiratory Journal.

[18]  M. A. Abdalla,et al.  Anti-nucleosome antibodies in systemic lupus erythematosus patients: Relation to anti-double stranded deoxyribonucleic acid and disease activity , 2017 .

[19]  A. Ishizu,et al.  NETosis markers: Quest for specific, objective, and quantitative markers. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[20]  C. Kallenberg,et al.  FSAP‐mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE , 2016, European journal of immunology.

[21]  M. Kaplan,et al.  At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases , 2016, Journal of leukocyte biology.

[22]  T. Gould,et al.  Release of Neutrophil Extracellular Traps by Neutrophils Stimulated With Antiphospholipid Antibodies: A Newly Identified Mechanism of Thrombosis in the Antiphospholipid Syndrome , 2015, Arthritis & rheumatology.

[23]  A. Blom,et al.  Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus , 2013, Arthritis Research & Therapy.

[24]  A. Blom,et al.  Neutrophil Extracellular Traps That Are Not Degraded in Systemic Lupus Erythematosus Activate Complement Exacerbating the Disease , 2012, The Journal of Immunology.

[25]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[26]  Matthias Kretzler,et al.  Netting Neutrophils Induce Endothelial Damage, Infiltrate Tissues, and Expose Immunostimulatory Molecules in Systemic Lupus Erythematosus , 2011, The Journal of Immunology.

[27]  M. Urowitz,et al.  SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation , 2011, Lupus.

[28]  Abdul Hakkim,et al.  Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis , 2010, Proceedings of the National Academy of Sciences.

[29]  M. Mukai.  [Systemic lupus erythematosus and nucleosome]. , 2006, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[30]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[31]  A. Zychlinsky,et al.  Neutrophil Extracellular Traps Kill Bacteria , 2004, Science.

[32]  D. Gladman,et al.  The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. , 2000, The Journal of rheumatology.

[33]  J. Piette,et al.  Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. , 1997, Arthritis and rheumatism.

[34]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[35]  G. Pruijn,et al.  NETosis, complement, and coagulation: a triangular relationship , 2018, Cellular & Molecular Immunology.

[36]  Guochun Wang,et al.  Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus. , 2014, Internal medicine.

[37]  R. Williams,et al.  Detection of nucleosome particles in serum and plasma from patients with systemic lupus erythematosus using monoclonal antibody 4H7. , 2001, The Journal of rheumatology.